Cerecin Announces Orphan Drug Designation from U.S. FDA for Tricaprilin in the Treatment of Infantile Spasms SINGAPORE AND DENVER, COLORADO, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Cerecin, a biopharmaceutical company focused on discovering and developing brain therapeutics, announced today that the U.S. Food...

U.S. FDA Grants Rare Pediatric Disease Designation to Cerecin’s Investigational Drug Tricaprilin for the Treatment of Infantile Spasms SINGAPORE AND DENVER, COLORADO , Oct. 08, 2020 (GLOBE NEWSWIRE) -- Cerecin, a biopharmaceutical company focused on discovering and developing brain therapeutics, announced that the U.S. Food and...

Cerecin appoints biotech veteran Joseph S. Zakrzewski as its new Chairman SINGAPORE AND DENVER, COLORADO, Dec. 20, 2019 (GLOBE NEWSWIRE) -- SINGAPORE AND DENVER, COLORADO, 20 December 2019 – Cerecin, an innovative biopharmaceutical company focused on brain health, today...

 Cerecin strengthens its leadership position in CNS drug development by adding a biotech veteran to the executive team Bruce Morimoto joins Cerecin as Vice President of Drug Development Denver, Colorado, Nov. 04, 2019 (GLOBE NEWSWIRE) -- Cerecin, a global healthcare company focused on developing brain health solutions and therapeutics for patients around the world, today announced...

Cerecin appoints Dr. Xiaoping Cao as Head of CMC Singapore, Jan. 07, 2019 (GLOBE NEWSWIRE) -- Cerecin appoints Dr. Xiaoping Cao as Head of CMC Dr. Cao will lead the Chemistry, Manufacturing and Controls (CMC) of Cerecin’s pipeline of highly...